Resonant magnetic disks for bioanalyte detection

ABSTRACT

Embodiments of the invention relate generally to ferromagnetic microdisks, methods of detecting target bioanalyte using ferromagnetic microdisks, and kits (such as for using in the laboratory setting) containing the reagents necessary to make, and/or use ferromagnetic microdisks for bioanalyte detection, depending on the user&#39;s planned application. The methods and products allow the fabrication of ferromagnetic microdisks, and their use in the detection of biological molecules with high sensitivity, little or no signal decay, improved safety, convenience, and lowered cost for use and disposal.

FIELD OF INVENTION

Embodiments of the invention relate to ferromagnetic microdisksbioconjugated to molecular probes, and methods of using bioconjugatedferromagnetic microdisks for detecting biological molecules(bioanalytes).

BACKGROUND

The ability to detect and identify trace quantities, of analytes hasbecome increasingly important in virtually every scientific discipline,ranging from part per billion analyses of pollutants in sub-surfacewater to analysis of cancer treatment drugs in blood serum.

With the advancement of technologies to make and detect biomolecules,there are multiple techniques that promise biological detection withsingle molecule sensitivity. However, many of these techniques have notyet found commercial applications or feasibility. The main reasons arethe complexity associated with these ultra-sensitive methods, the costs,and the potential biohazards associated with the reagents. Many methodsrequire multiple steps of chemical treatments, bulky and expensiveinstruments, and/or extreme care in sample handling and observation.These are not ideal for practical applications that require easy andreliable measurements that are flexible enough for user's needs.

Additionally, many of the currently used methods of detectingbioanalytes rely on markers or “tags” that bind to the bioanalytes andare detected, thereby indirectly detecting the bioanalytes(s) ofinterest. However, the markers or tags such as radioisotope-labeledprobes, or fluorescent markers, can lose their signal intensity overtime. For example, radioisotopes commonly used as “tags” or “markers”decay over time, causing a gradual loss of signal that can be detected.Because of this, some experiments need to be conducted rapidly beforethe signal decays beyond the limits of detection. Similarly, fluorescentprobes are subject to “photobleaching” wherein exposure to ambient lightcauses the fluorescent probe to bleach or fade away. Again, oftenexperiments need to be conducted quickly before photobleaching occurs,or inconveniently in a dark setting so as to avoid photobleaching.

Safety is another consideration. Radioactive labels and their requiredreagents must be used in carefully monitored situations due to theirknown biologic hazards. Radioactive wastes produced from commondetection methods must be carefully disposed of so as to avoidenvironmental contamination. Similarly, the toxicity of cadmium inquantum dots and relatively large size of dye-loaded particles havelimited their applications. Although very small size (down to 10 nm indiameter) detection has been achieved for conjugated polymer particles,their signal intensity is lower than the larger fluorescent particles.Lower signal intensity makes the particles more difficult to detect withconventional techniques.

Finally, the cost of radioactive and fluorescent substances can besubstantial, both in terms of acquisition, use, safety monitoring, andtheir proper monitoring and disposal.

Accordingly, there is a need for a reagents methods of bioanalytedetection wherein the marker to be detected exhibits little or no signaldecay, and can be safely utilized in a variety of environments withoutposing risks to the user or to the environment. Preferably, a markerwould have a high safety profile, exhibit a long (non or low-decaying)signal intensity, and be available to users at a low cost for reagentuse and disposal.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a cross-sectional schematic illustrating skeleton componentsof tag-based detection of biomolecules (bioanalytes) using magneticvortex resonance labeling and detection.

FIG. 2 shows the microfabrication steps to make ferromagnetic microdisks(top), and an electron micrograph of fabricated microdisks (bottom).

FIG. 3 shows the resonance frequency characteristics exhibited byferromagnetic microdisks having three different geometries (L=thickness,R=radius).

DETAILED DESCRIPTION

Embodiments of the invention relate to ferromagnetic microdisksbioconjugated to molecular probes, and methods of using bioconjugatedferromagnetic microdisks for detecting biological molecules(bioanalytes) with high sensitivity and improved ease of use and safetyprofiles. The embodiments are especially directed to making andutilizing conjugated ferromagnetic microdisks that exhibit a uniqueresonance frequency depending on the geometry of the ferromagneticmicrodisk, in which the resonance frequency can be detected byappropriate instruments for the detection of one or more bioanalyte ofinterest. Because the resonance frequency exhibited by the ferromagneticmicrodisk is a magnetic signal, it does not decay or diminish over time.The invention transcends several scientific disciplines such as polymerchemistry, biochemistry, molecular biology, medicine, and medicaldiagnostics.

As used in the specification and claims, the singular forms “a,” “an,”and “the” include plural references unless the context clearly dictatesotherwise. For example, the term “an array” may include a plurality ofarrays unless the context clearly dictates otherwise.

A “ferromagnetic microdisk” is one or more of an intentionally createddevices that can be prepared by a variety of methods known in the art,such as photolithography. The ferromagnetic microdisks exhibit (i.e.,emit) a unique magnetic vortex resonance depending on the geometry ofthe microdisk, such as the diameter and thickness of the microdisk.Ferromagnetic microdisks can be attached (bioconjugated) to chosenmolecular probes that are specific to various bioanalytes of interest.The unique vortex resonance exhibited by the ferromagnetic microdisk canbe detected using common apparatus in the art.

The terms “nanomaterial” and “nanoparticle” as used herein refer to astructure, a device, or a system having a dimension at the atomic,molecular or macromolecular levels, in the length scale of approximately1-1000 nanometer range, preferably in the range of about 2 m to about200 mm, more preferably in the range of about 2 nm to about 50 nm.

The term “bioanalyte,” “analyte,” “target,” or “target molecule” refersto a molecule of interest in a sample that is to be detected, analyzed,and/or quantified in some manner. Examples of bioanalytes include, butare not limited to, amino acids, peptides, polypeptides, proteins,glycoproteins, lipoproteins, nucleosides, nucleotides, oligonucleotides,nucleic acids, sugars, carbohydrates, oligosaccharides, polysaccharides,fatty acids, lipid, hormones, metabolites, cytokines, chemokines,receptors, neurotransmitters, antigens, allergens, antibody, substrates,metabolites, cofactors, inhibitors, drugs, pharmaceuticals, nutrients,prions, toxins, poisons, explosives, pesticides, chemical warfareagents, biohazardous agents, radioisotopes, vitamins, heterocyclicaromatic compounds, carcinogens, mutagens, narcotics, amphetamines,barbiturates, hallucinogens, and waste products and/or contaminants. Incertain embodiments of the invention, one or more bioanalytes may becontacted with, and joined to such as by hybridization, one or morebiomolecular probes, as disclosed below, which are themselves bound toferromagnetic microdisks.

The sample such as a bioanalyte in the embodiments of this invention canbe in the form of solid, liquid or gas, or solution. The sample can beanalyzed by the embodiments of the methods and devices of this inventionwhen the sample is at room temperature, and at lower than or higher thanthe room temperature. Samples may be obtained from any source, biologicor non-biologic.

Further, the bioanalyte could be an organic or inorganic molecule. Someexamples of analytes may include a small molecule, a biomolecule, or ananomaterial such as but not necessarily limited to a small moleculethat is biologically active, nucleic acids and their sequences, peptidesand polypeptides, as well as nanostructure materials chemically modifiedwith biomolecules or small molecules capable of binding to molecularprobes such as chemically modified carbon nanotubes, carbon nanotubebundles, nanowires, nanoclusters or nanoparticles. The bioanalytemolecule may be a fluorescently labeled molecule, such as DNA or RNA.

The term “fluid” used herein means an aggregate of matter that has thetendency to assume the shape of its container, for example a liquid orgas. Analytes in fluid form can include fluid suspensions and solutionsof solid particle analytes.

The term “bi-functional linker group” refers to an organic chemicalcompound that has at least two chemical groups or moieties, such as forexample, carboxyl group, amine group, thiol group, aldehyde group, epoxygroup, that can be covalently modified specifically; the distancebetween these groups is equal to or greater than 5-carbon bonds.

The term “molecular probe,” “biomolecular probe,” “capture molecule,” or“affinity agent” refers to a molecule or group/collection of moleculesthat is attached (“bioconjugated”), reversibly or irreversibly, to aferromagnetic microdisk. The molecular probe generally, but notnecessarily, also binds to one or more bioanalytes of interest, asdescribed above. The biomolecular probe is typically a nucleotide, anoligonucleotide, or a protein, but can also be a small molecule,biomolecule, or nanomaterial such as, but not necessarily limited to, asmall molecule that is biologically active, nucleic acids and theirsequences, peptides and polypeptides, as well as nanostructure materialschemically modified with biomolecules or small molecules capable ofbinding to a target molecule that is bound to a probe molecule to form acomplex of the capture molecule, target molecule and the probe molecule.The capture molecule may be fluorescently labeled DNA or RNA. Thecapture molecule may or may not be capable of binding to just the targetbioanalyte or just the probe molecule. Other molecular probes include,for example, antibodies, antibody fragments, antigens, epitopes,lectins, proteins, polypeptides, receptor proteins, ligands, hormones,vitamins, metabolites, substrates, inhibitors, cofactors,pharmaceuticals, aptamers, cytokines and neurotransmitters.

The term “molecule” generally refers to a macromolecule or polymer asdescribed herein. However, SEF nanoparticles comprising singlemolecules, as opposed to macromolecules or polymers, are also within thescope of the embodiments of the invention.

A “macromolecule” or “polymer” comprises two or more monomers covalentlyjoined. The monomers may be joined one at a time or in strings ofmultiple monomers, ordinarily known as “oligomers.” Thus, for example,one monomer and a string of five monomers may be joined to form amacromolecule (polymer) of six monomers. Similarly, a string of fiftymonomers may be joined with a string of hundred monomers to form amacromolecule or polymer of one hundred and fifty monomers. The termpolymer as used herein includes, for example, both linear and cyclicpolymers of nucleic acids, polynucleotides, polynucleotides,polysaccharides, oligosaccharides, proteins, polypeptides, peptides,phospholipids and peptide nucleic acids (PNAs). The peptides includethose peptides having either α-, β-, or ω-amino acids. In addition,polymers include heteropolymers in which a known drug is covalentlybound to any of the above, polyurethanes, polyesters, polycarbonates,polyureas, polyamides, polyethyleneimines, polyarylene sulfides,polysiloxanes, polyimides, polyacetates, or other polymers which will beapparent upon review of this disclosure.

The term “nucleotide” includes deoxynucleotides and analogs thereof.These analogs are those molecules having some structural features incommon with a naturally occurring nucleotide such that when incorporatedinto a polynucleotide sequence, they allow hybridization with acomplementary polynucleotide in solution. Typically, these analogs arederived from naturally occurring nucleotides by replacing and/ormodifying the base, the ribose or the phosphodiester moiety. The changescan be tailor-made to stabilize or destabilize hybrid formation, or toenhance the specificity of hybridization with a complementarypolynucleotide sequence as desired, or to enhance stability of thepolynucleotide.

The term “polynucleotide” or “nucleic acid” as used herein refers to apolymeric form of nucleotides of any length, either ribonucleotides ordeoxyribonucleotides, that comprise purine and pyrimidine bases, orother natural, chemically or biochemically modified, non-natural, orderivatized nucleotide bases. Polynucleotides of the embodiments of theinvention include sequences of deoxyribopolynucleotide (DNA),ribopolynucleotide (RNA), or DNA copies of ribopolynucleotide (cDNA)which may be isolated from natural sources, recombinantly produced, orartificially synthesized. A further example of a polynucleotide of theembodiments of the invention may be polyamide polynucleotide (PNA). Thepolynucleotides and nucleic acids may exist as single-stranded ordouble-stranded. The backbone of the polynucleotide can comprise sugarsand phosphate groups, as may typically be found in RNA or DNA, ormodified or substituted sugar or phosphate groups. A polynucleotide maycomprise modified nucleotides, such as methylated nucleotides andnucleotide analogs. The sequence of nucleotides may be interrupted bynon-nucleotide components. The polymers made of nucleotides such asnucleic acids, polynucleotides and polynucleotides may also be referredto herein as “nucleotide polymers.

An “oligonucleotide” is a polynucleotide having 2 to 20 nucleotides.Analogs also include protected and/or modified monomers as areconventionally used in polynucleotide synthesis. As one of skill in theart is well aware, polynucleotide synthesis uses a variety ofbase-protected nucleoside derivatives in which one or more of thenitrogens of the purine and pyrimidine moiety are protected by groupssuch as dimethoxytrityl, benzyl, tert-butyl, isobutyl and the like.

For instance, structural groups are optionally added to the ribose orbase of a nucleoside for incorporation into a polynucleotide, such as amethyl, propyl or allyl group at the 2′-O position on the ribose, or afluoro group which substitutes for the 2′-O group, or a bromo group onthe ribonucleoside base. 2′-O-methyloligoribonucleotides (2′-O-MeORNs)have a higher affinity for complementary polynucleotides (especiallyRNA) than their unmodified counterparts. Alternatively, deazapurines anddeazapyrimidines in which one or more N atoms of the purine orpyrimidine heterocyclic ring are replaced by C atoms can also be used.

The phosphodiester linkage, or “sugar-phosphate backbone” of thepolynucleotide can also be substituted or modified, for instance withmethyl phosphonates, O-methyl phosphates or phosphororthioates. Anotherexample of a polynucleotide comprising such modified linkages forpurposes of this disclosure includes “peptide polynucleotides” in whicha polyamide backbone is attached to polynucleotide bases, or modifiedpolynucleotide bases. Peptide polynucleotides which comprise a polyamidebackbone and the bases found in naturally occurring nucleotides arecommercially available.

When the macromolecule of interest is a peptide, the amino acids can beany amino acids, including α, β, or ω-amino acids. When the amino acidsare α-amino acids, either the L-optical isomer or the D-optical isomermay be used. Additionally, unnatural amino acids, for example,β-alanine, phenylglycine and homoarginine are also contemplated by theembodiments of the invention. These amino acids are well-known in theart.

A “peptide” is a polymer in which the monomers are amino acids and whichare joined together through amide bonds and alternatively referred to asa polypeptide. In the context of this specification it should beappreciated that the amino acids may be the L-optical isomer or theD-optical isomer. Peptides are two or more amino acid monomers long, andoften more than 20 amino acid monomers long.

A “protein” is a long polymer of amino acids linked via peptide bondsand which may be composed of two or more polypeptide chains. Morespecifically, the term “protein” refers to a molecule composed of one ormore chains of amino acids in a specific order; for example, the orderas determined by the base sequence of nucleotides in the gene coding forthe protein. Proteins are essential for the structure, function, andregulation of the body's cells, tissues, and organs, and each proteinhas unique functions. Examples of proteins include hormones, enzymes,and antibodies.

The term “sequence” refers to the particular ordering of monomers withina macromolecule and it may be referred to herein as the sequence of themacromolecule.

A “ligand” is a molecule that is recognized by a particular receptor.Examples of ligands that can be investigated by this invention include,but are not restricted to, agonists and antagonists for cell membranereceptors, toxins and venoms, viral epitopes, hormones, hormonereceptors, peptides, enzymes, enzyme substrates, cofactors, drugs (e.g.opiates, steroids, etc.), lectins, sugars, polynucleotides, nucleicacids, oligosaccharides, proteins, and monoclonal antibodies.

A “receptor” is molecule that has an affinity for a given ligand.Receptors may-be naturally-occurring or manmade molecules. Also, theycan be employed in their unaltered state or as aggregates with otherspecies. Receptors may be attached, covalently or noncovalently, to abinding member, either directly or via a specific binding substance.Examples of receptors which can be employed by this invention include,but are not restricted to, antibodies, cell membrane receptors,monoclonal antibodies and antisera reactive with specific antigenicdeterminants (such as on viruses, cells or other materials), drugs,polynucleotides, nucleic acids, peptides, cofactors, lectins, sugars,polysaccharides, cells, cellular membranes, and organelles. Receptorsare sometimes referred to in the art as anti-ligands. As the term“receptors” is used herein, no difference in meaning is intended. A“Ligand Receptor Pair” is formed when two macromolecules have combinedthrough molecular recognition to form a complex. Other examples ofreceptors which can be investigated by this invention include but arenot restricted to:

a) Microorganism receptors: Determination of ligands which bind toreceptors, such as specific transport proteins or enzymes essential tosurvival of microorganisms, is useful in developing a new class ofantibiotics. Of particular value would be antibiotics againstopportunistic fungi, protozoa, and those bacteria resistant to theantibiotics in current use.

b) Enzymes: For instance, one type of receptor is the binding site ofenzymes such as the enzymes responsible for cleaving neurotransmitters;determination of ligands which bind to certain receptors to modulate theaction of the enzymes which cleave the different neurotransmitters isuseful in the development of drugs which can be used in the treatment ofdisorders of neurotransmission.

c) Antibodies (Abs): For instance, the invention may be useful ininvestigating the ligand-binding site on the antibody molecule whichcombines with the epitope of an antigen of interest; determining asequence that mimics an antigenic epitope may lead to the-development ofvaccines of which the immunogen is based on one or more of suchsequences or lead to the development of related diagnostic agents orcompounds useful in therapeutic treatments such as for auto-immunediseases (e.g., by blocking the binding of the “anti-self” antibodies).There are monoclonal antibodies (mAb) and polyclonal antibodies (pAb).

d) Nucleic Acids: Sequences of nucleic acids may be synthesized toestablish DNA or RNA binding sequences. Certain sequence of nucleicacids, called aptamer, can bind to proteins or peptides.

e) Catalytic Polypeptides: Polymers, preferably polypeptides, which arecapable of promoting a chemical reaction involving the conversion of oneor more reactants to one or more products. Such polypeptides generallyinclude a binding site specific for at least one reactant or reactionintermediate and an active functionality proximate to the binding site,which functionality is capable of chemically modifying the boundreactant.

f) Hormone receptors: Examples of hormones receptors include, e.g., thereceptors for insulin and growth hormone. Determination of the ligandswhich bind with high affinity to a receptor is useful in the developmentof, for example, an oral replacement of the daily injections whichdiabetics take to relieve the symptoms of diabetes. Other examples arethe vasoconstrictive hormone receptors; determination of those ligandswhich bind to a receptor may lead to the development of drugs to controlblood pressure.

g) Opiate receptors: Determination of ligands which bind to the opiatereceptors in the brain is useful in the development of less-addictivereplacements for morphine and related drugs.

A “linker” molecule refers to any of those molecules described supra,such as for example molecular probes, and preferably should be about 4to about 100 atoms long to provide sufficient exposure. The linkermolecules may be, for example, aryl acetylene, alkane derivatives,ethylene glycol oligomers containing 2-10 monomer units, diamines,diacids, amino acids, among others, and combinations thereof.Alternatively, the linkers may be the same molecule type as that beingsynthesized (i.e., nascent polymers), such as polynucleotides,oligopeptides, or oligosaccharides.

The term “fluid” used herein means an aggregate of matter that has thetendency to assume the shape of its container, for example a liquid orgas. Analytes in fluid form can include fluid suspensions and solutionsof solid particle analytes.

The term “attached,” as in, for example, the “attachment” of a molecularprobe to a ferromagnetic microdisk, includes covalent binding,adsorption, and physical immobilization. The terms “associated with,”“binding,” and “bound” are identical in meaning to the term “attached.”Attachment of molecular probe to ferromagnetic microdisk, or molecularprobe to bioanalyte; can be permanent or reversible.

The term “permalloy” refers to a nickel iron magnetic alloy.Generically, it refers to an alloy with about 20% iron and 80% nickelcontent (i.e., Ni80Fe20). Permalloy has a high magnetic permeability,low coercivity, near zero magnetostriction, and significant anisotropicmagnetoresistance. This alloy is used, for example, in transformerlaminations and magnetic recording head sensors. Permalloy's electricalresistivity generally varies within the range of 5% depending on thestrength of the magnetic field. The low magnetostriction is helpful forindustrial applications, where variable stresses in thin films wouldotherwise cause a ruinously large variation in magnetic properties.Other compositions of permalloy are available, designated by a numericalprefix denoting the percentage of nickel in the alloy, for example 45permalloy containing 45% nickel, and 55% iron. Molybdenum permalloy isan alloy of 81% nickel, 17% iron and 2% molybdenum.

Other ferromagnetic materials are encompassed by embodiments of theinvention. For example, ferromagnetic microdisks can be fabricated withsubstances such as CoNiFe, CoFe, CoFeCu, CoZrTa, and other ferromagneticmetals or alloys.

Embodiments of the invention relate generally to ferromagneticmicrodisks bound to molecular probe, methods of detecting targetbioanalyte using ferromagnetic microdisks, and kits (such as for usingin the laboratory setting) containing the reagents necessary to make,and/or use ferromagnetic microdisks for bioanalyte detection, dependingon the user's planned application. The methods and products allow thefabrication of ferromagnetic microdisk/molecular probe complexes, andtheir use in the detection of biological molecules (bioanalytes) withhigh sensitivity, little or no signal decay, improved safety,convenience, and lowered cost of use and disposal. The embodiments areespecially directed to utilizing ferromagnetic microdisks exhibitingunique resonance frequency as “tags,” and identifying the tags usingdetection of the unique resonance frequency by known means, or otherdetection methods wherein ferromagnetic microdisks can be detectedand/or observed. Ferromagnetic microdisks can be used in solution orattached to a substrate for bioanalyte detection, depending on userneeds.

One embodiment is a ferromagnetic microdisk, constructed from aferromagnetic material, that exhibits a unique resonance frequencydetermined by the geometry of the microdisk, and a molecular probeattached to the ferromagnetic microdisk. Preferably, the ferromagneticmaterial is permalloy.

Preferably, ferromagnetic microdisks have a diameter of less than about3 μm and a thickness of less than about 50 nm. More preferably,ferromagnetic microdisks have a diameter of about 1.1 μm to about 2.2μm, and a thickness of about 20 nm to about 40 nm.

Preferably, ferromagnetic microdisks are fabricated, and the geometry isdetermined, by photolithography.

In embodiments of the invention, the ferromagnetic microdisks exhibit aunique resonance frequency ranging from about 25 mHz to about 400 mHz.Preferably, the unique resonance frequency is from about 80 to about272. mHz. More preferably, the resonance frequency is about 83, 162, or272 mHz.

Preferably, ferromagnetic microdisks of the invention are attached tomolecular probes. Molecular probes include, for example, antibody,antigen, ligand, receptor, aptamer, or a nucleic acid. More preferably,the molecular probe comprises an antibody or a nucleic acid. Morepreferably, the molecular probe attached to the ferromagnetic diskcomprises protein.

Another embodiment is a method of detecting a target bioanalyte, such asa biomolecule of interest, with a ferromagnetic microdisk by attaching(“bioconjugating”) one or more molecular probes to one or moreferromagnetic microdisks that are made of a ferromagnetic material andexhibit a unique resonance frequency; contacting the bioconjugatedferromagnetic microdisk with at least one target bioanalyte of interest;binding the molecular probe to the target analyte, and detecting theunique resonance frequency exhibited by the ferromagnetic microdisk,thereby detecting presence of the ferromagnetic microdisk and thus thepresence of at least one target bioanalyte which has bound to themolecular probe on the ferromagnetic microdisk.

Preferably, the molecular probe attached to the ferromagnetic disk ischosen from an antibody, antigen, ligand, receptor, aptamer, and nucleicacid. More preferably, the molecular probe comprises protein.

In one embodiment of the invention, the target bioanalyte is present ina solid sample. In another embodiment, the target bioanalyte is presentin a solution. In certain embodiments, the target bioanalyte is bound toa solid or semisolid support or matrix.

Preferably, the target bioanalyte is present in vitro. More preferably,the target bioanalyte is present in vivo.

In other embodiments of the invention, the bioanalyte to be detected ispresent in a non-living sample, such as for example, a food sample, soilsample, or water sample. Embodiments of the invention are not limited tobiological samples or tissues, and can be used in industry, geology, ancontamination detection.

Another embodiment of the invention is a kit that includes one or moreferromagnetic microdisks and one or more molecular probes attached tothe ferromagnetic microdisk, wherein the ferromagnetic microdiskscomprise a ferromagnetic material and exhibit a unique resonancefrequency determined by the geometry of the microdisk.

Preferably, the ferromagnetic microdisks comprise permalloy film.

Preferably, the molecular probe is selected from the group consisting ofantibody, antigen, ligand, receptor, aptamer, and nucleic acid. Morepreferably, the molecular probe comprises protein.

Embodiments of the invention encompass ferromagnetic microdisks thatinclude a ferromagnetic material and exhibit a unique resonancefrequency determined by the geometry of the microdisk. The manufactureand resonance frequency characteristics of ferromagnetic microdisks havebeen described in the art (see Novosad, et al., Magnetic VortexResonance in Patterned Ferromagnetic Dots, Physical Review, B72,024455-1-5 (2005), the entire disclosure of which is hereby incorporatedby reference).

Embodiments of this invention addresses the the problem of: (1) targetbioanalyte detection when present in low levels in the target sample;(2) highly sensitive detection of antigens, antibodies, and viruses, andother bioanalytes; (3) using markers or tags that are safe to the useand environmentally sound, are easy to use, and that exhibit a signalthat does not decay or degrade over time or with use. As a result,embodiments of the invention simplify sample preparation andsignificantly lower the costs and biohazards associated with bioanalytedetection.

As described, embodiments of this invention provide highly sensitivedevices and methods for bioanalyte detection. With a biomolecular probeattached to ferromagnetic microdisk, mass sensitivity can be estimatedas follows. Note that each spectrum shown in FIG. 3 was collected from˜1200 microdisks. Mass of biomolecule is ˜1000 kDa (kilo Dalton. 1 Da˜1.66×10⁻²⁷ kg). As examples, the mass of yeast protein and titinsprotein is 53 kDa and 3000 kDa, respectively. The mass sensitivity canbe calculated as follows.

1200 biomolecules×1000 kDa=1,200,000 kDa−2×10⁻¹⁸ kg.

The mass sensitivity is therefore ˜10⁻¹⁸ kg.

In the embodiments of the invention, permalloy films are preferredsubstrate for ferromagnetic microdisks. Such films have been shown to beuseful for the fabrication of ferromagnetic microdisks. However, otherferromagnetic materials can be used, such as for example CoNiFe, CoFe,CoFeCu, CoZrTa, and other ferromagnetic metals or alloys.

Some of the technical advantages of the embodiments of the inventioninclude the following:

-   (1) Target bioanalytes (e.g., proteins or nucleic acids) need not be    labeled or amplified (DNA). This is because ferromagnetic microdisk    detection is a label-free strategy that is superior to fluorescence    technology in which target samples must be labeled with fluorescent    molecules that are prone to photobleaching. Thus, tedious,    error-prone, costly, and environmentally unfriendly (e.g.,    radioisotope labeling) sample preparation steps can be avoided.-   (2) Multiple targets can be detected at the same time in one sample    by using multiple ferromagnetic microdisks variable bioconjugated    molecular probes. Ferromagnetic microdisks can be “free” in a    sample, or alternatively, bound to a solid or semisolid substrate,    such as for example, an array, wherein a test sample is applied to    the array and for bioanalyte detection with complementary molecular    probes. Ferromagnetic microdisks can be used in discrete units,    i.e., ferromagnetic microdisks with one type of molecular probe that    is specific to one particular bioanalyte, or alternatively,    ferromagnetic microdisks can be used with a library of molecular    probes that are specific to a myriad of bioanalytes. This latter    embodiment is advantageous in the fabrication and use of    ferromagnetic microdisks in an array.-   (3) Each bioanalyte molecule detection can be verified by    duplication using the same detection probe but with a different    ferromagnetic microdisk. The multiplicity of ferromagnetic microdisk    detection allows redundant measurement, thereby providing greater    control increased credibility of the test results.-   (4) The structure of ferromagnetic microdisks and their respective    attached biomolecular probes can be easily fine-tuned to meet    specific applications in diagnostics and drug discovery.

Embodiments of this invention have several useful applications. Forexample, ferromagnetic microdisks can be employed for theultra-sensitive detection of bioanalytes including, antibodies,antigens, biomarkers, allergens, ligands, metabolites, virus, bacteria,tumor cells, etc. The ability to detect, locate, and/or quantifybioanalytes allows for diagnostic use, treatment, and/or monitoring ofspecific diseases, physiological conditions (normal or abnormal),conditions, and therapies. For example, detection of abnormal proteinsin human disease could detected. As another example, the normal signaltransduction inside, or outside cells could be detected and monitored.It is envisioned that embodiments of the invention could be used in vivoor in vitro for screening purposes, i.e., high throughput methods ofevaluating pathological conditions. High-throughput drug discoveryscreening is another example where embodiments of the invention would beuseful.

Resonance frequency detection, for example with equipment to measureresonance frequency such as a network analyzer could be employed in bothnormal physiological systems (e.g., at the cellular, tissue, and wholeanimal level), and also in pathological states for disease evaluation.Embodiments of the invention are also useful in flow cytometry,environmental monitoring, and food analysis.

In order to provide users with the ability to efficiently utilizeembodiments of the invention, the present invention contemplates methodsand kits for screening samples containing suspected analytes of interestthat could be detected with ferromagnetic microdisks. The kits containthe reagents necessary to manufacture ferromagnetic microdisks,including the disks, reagents for attaching one or more molecularprobe(s) that can bind to the target bioanalyte of interest. Such kitsare advantageous for users who want to create ferromagnetic microdisksand attach molecular probes that will be useful in specificapplications, such as for example, locating, quantifying, and oranalyzing particular target bioanalytes of interest.

For example, one kit contains all the reagents necessary for theproduction of ferromagnetic microdisks, and a molecular probe, such as aparticular receptor, that is conjugated to the ferromagnetic microdisks;in this manner, the ferromagnetic microdisk has been “tagged” with amolecular probe. The particular receptor, when contacted to a sample ofinterest, will bind to a cellular protein (bioanalyte) of interest thatis specific for, or complementary to, the molecular probe attached tothe ferromagnetic microdisk. The target sample containing bioanalyte canbe derived from, for example, a cell culture (i.e., in vitro), or from amammalian sample (i.e., in vivo). After contacting the taggedferromagnetic microdisk with bioanalyte of interest, the ferromagneticmicrodisk is detected based on its unique resonance frequency (using,for example, detectors that recognize the characteristic magnetic vortexresonance frequency emitted by the ferromagnetic microdisk), therebydetecting the presence (or absence), quantity, and location of thetarget cellular protein (i.e., bioanalyte) of interest. This example ismerely illustrative, and not intended to be limiting.

Although embodiments have been described in which small molecules andproteins are described as being the analytes, it is understood, however,that the same process and tools can be used to detect the binding of avariety of analytes to one another and the invention is not limited tojust the binding of small molecules to proteins.

EXAMPLE 1

FIG. 1 shows an exemplary ferromagnetic microdisk that is attached to amolecular probe (“linker”) which acts as a binding partner to abioanalyte of interest. The ferromagnetic microdisk is made of aferromagnetic material, such as permalloy, that is well known in theart. Ferromagnetic microdisks exhibit a unique resonance frequency basedon their geometry, such as the diameter and thickness of the microdisk;by altering the geometric paramters, ferromagnetic microdisk are madewith specific unique resonance frequencies.

As shown in FIG. 1, tagged biomolecule(s) approach the read line (whichare simply conducting lines such as copper), the ferromagnetic microdiskis detected by evaluating the characteristic magnetic vortex resonancefrequency. Read lines may be microwave coplanar waveguides used togenerate magnetic field and collect (i.e., detect) the frequencyspectrum. Microchannel may be formed in order to provide closed volumewithin which all biomolecules and ferromagnetic microdisks can beconfined.

The ferromagnetic microdisk, preferably the outer surface therof, isbioconjugated to a molecular probe and the complex is used forbioanalyte detection. The ferromagnetic microdisks are functionalizedwith an molecular probe, such as an amine group. Various bioanalytes ofinterest in a sample are contacted with, and conjugated to, thefunctionalized ferromagnetic microdisks through bioconjugation methodsfor that are well known in the art, such as hybridization. Bioanalytesof interest to be detected include, for example, proteins, antibodies,enzymes, nucleic acids (DNA, RNA, oligonucleotides), antigen, peptides,ligands, receptors, small molecules, metabolites, etc. Although thebiological applications of the bioconjugated ferromagnetic microdisk isare immense, detection of signature antibody, autoantibody, antigen,virus and bacterium are of special interest for disease diagnostics andtreatment monitoring.

The bioanalyte of interest is now bound to one or more ferromagneticmicrodisks because the molecular probe (conjugated to the surface of theferromagnetic microdisk) also binds to the bioanalyte of interest. Thebionanlyte of interest is now located and quantified by detection of theunique resonance frequency emitted by the bound ferromagnetic microdisk.The resonance frequency is detected with a magnetic signal detector andnetwork analyzer; such methods that are well known in the art fordetecting and quantify magnetic signals.

EXAMPLE 2

FIG. 2 shows a method of manufacturing ferromagnetic microdisks.Ferromagnetic microdisks are made by photolithography methods well knownin the art, wherein ferromagnetic materials such as permalloy undergospin-coating, resist development, and E-beam metallization. The uniqueresonance frequency is determined, and can be altered by, changing thegeometry of the microdisk, including changing the diameter and thicknessof the microdisk. The manufacture and resonance frequencycharacteristics of ferromagnetic microdisks have been described in theart (see Novo sad, et al., Magnetic Vortex Resonance in PatternedFerromagnetic Dots, Physical Review, B72, 024455-1-5 (2005); see alsoNovosad, et al., Ferromagnetic Microdisks: Novel magnetic Particles forBiomedical Applications, NSTI-Nanotech, vol. 1:308-311 (2005) (theentire disclosures of which are hereby incorporated by reference).

EXAMPLE 3

Permalloy ferromagnetic microdisks are manufactured in a variety ofthicknesses and diameters by methods known in the art. Three microdiskgeometries are made to demonstrate the effect of variable geometry onresonance frequency:

Diameter (μm) Thickness (nm) Frequency (mHz) 2.0 20 83 2.2 40 162 1.1 40272

FIG. 3 shows the data for these microdisks. The resonances at 83, 162,and 172 mHz, respectively, are in agreement with the eigenfrequencies ofthe collective spin excitations simulated micromagnetically andanalytically. The number of frequency sweeps average 320, 160, and 640respectively.

The resonance frequency of each ferromagnetic microdisk can be detected,thereby demonstrating the presence of one or more microdisks having thatunique resonance frequency. In this manner, a user can bioconjugate amolecular probe to a ferromagnetic microdisk of known unique resonancefrequency. The molecular probe/ferromagnetic disk is a “complex” thatcan be used to target, locate, identify, and quantify bioanalytes ofinterest that are complementary, or bind to, the molecular probe.Molecular probes, methods of bioconjugation (molecular probe toferromagnetic disk), as well as binding of ferromagnetic disk/molecularprobe complex to bioanalyte of interest (for example, hybridization orchemical linking) are well known in the art and easily within the skillof a person in the art.

Conveniently, either the sample or the ferromagnetic disk/molecularprobe complex(es) can be applied and bound to a solid or semi solidsubstrate, such as for example, glass. In this manner, manual orautomated dispensers (such as for example, robots) can be used toproduce “arrays” containing multiple different ferromagnetic disks, eachwith their own unique resonance frequency or molecular probe.Accordingly, a sample can be contact to the ferromagnetic disk array,and several different bioanalytes of interest can be evaluated in oneexperiment, allowing for high throughput uses. Array formats andtechnologies, such as robotic dispensers, array substrates, and patternalgorithms are well known in the art. Advantageously, in such array orhigh throughput uses, the unique resonance frequency “signal” emitted bythe ferromagnetic disk/molecular probe complex does not fade or decayover time. Also, such signals are not harmful to users, as areradioisotopes. Ferromagnetic disks can be discarded without concern forradioactive contamination of the environment.

Commercial applications for the products and methods described hereininclude environmental toxicology and remediation, biomedicine, materialsquality control, food and agricultural products monitoring, anestheticdetection, automobile oil or radiator fluid monitoring, breath alcoholanalyzers, hazardous spill identification, explosives detection,fugitive emission identification, medical diagnostics, fish freshness,detection and classification of bacteria and microorganisms both invitro and in vivo for biomedical uses and medical diagnostic uses,monitoring heavy industrial manufacturing, ambient air monitoring,worker protection, emissions control, product quality testing, leakdetection and identification, oil/gas petrochemical applications,combustible gas detection, H₂S monitoring, hazardous leak detection andidentification, emergency response and law enforcement applications,illegal substance detection and identification, arson investigation,enclosed space surveying, utility and power applications, emissionsmonitoring, transformer fault detection, food/beverage/agricultureapplications, freshness detection, fruit ripening control, fermentationprocess monitoring and control applications, flavor composition andidentification, product quality and identification, refrigerant andfumigant detection, cosmetic/perfume/fragrance formulation, productquality testing, personal identification,chemical/plastics/pharmaceutical applications, leak detection, solventrecovery effectiveness, perimeter monitoring, product quality testing,hazardous waste site applications, fugitive emission detection andidentification, leak detection and identification, perimeter monitoring,transportation, hazardous spill monitoring, refueling operations,shipping container inspection, diesel/gasoline/aviation fuelidentification, building/residential natural gas detection, formaldehydedetection, smoke detection, fire detection, automatic ventilationcontrol applications (cooking, smoking, etc.), air intake monitoring,hospital/medical anesthesia & sterilisation gas detection, infectiousdisease detection and breath applications, body fluids analysis,pharmaceutical applications, drug discovery, telesurgery, and the like.

This application discloses several numerical range limitations thatsupport any range within the disclosed numerical ranges even though aprecise range limitation is not stated verbatim in the specificationbecause the embodiments of the invention could be practiced throughoutthe disclosed numerical ranges. Finally, the entire disclosure of thepatents and publications referred in this application, if any, arehereby incorporated herein in entirety by reference.

1. A ferromagnetic microdisk comprising: a ferromagnetic material; and amolecular probe attached to the ferromagnetic microdisk, wherein theferromagnetic microdisk has a unique magnetic vortex resonance frequencydetermined by a geometry of the ferromagnetic microdisk.
 2. Theferromagnetic microdisk of claim 1 wherein the ferromagnetic material isselected from the group consisting of permalloy, CoNiFe, CoFe, CoFeCu,CoZrTa, and other ferromagnetic metals or alloys.
 3. The ferromagneticmicrodisk of claim 1 wherein the ferromagnetic material is permalloy. 4.The ferromagnetic microdisk of claim 1 wherein the geometry of themicrodisk is determined by photolithography.
 5. The ferromagneticmicrodisk of claim 1 wherein the ferromagnetic microdisk has a diameterfrom about 0.5 μm to about 3.0 μm.
 6. The ferromagnetic microdisk ofclaim 1 wherein the ferromagnetic microdisk has a diameter of about 1.1μm.
 7. The ferromagnetic microdisk of claim 1 wherein the ferromagneticmicrodisk has a diameter of about 2.2 μm.
 8. The ferromagnetic microdiskof claim 1 wherein the ferromagnetic microdisk has a thickness fromabout 10 nanometers to about 50 nanometers.
 9. The ferromagneticmicrodisk of claim 1 wherein the ferromagnetic microdisk has a thicknessof about 20 nanometers.
 10. The ferromagnetic microdisk of claim 1wherein the ferromagnetic microdisk has a thickness of about 40nanometers.
 11. The ferromagnetic microdisk of claim 1 wherein theunique magnetic vortex resonance frequency is from about 20 megahertz toabout 400 megahertz.
 12. The ferromagnetic microdisk of claim 1 whereinthe unique magnetic vortex resonance frequency is about 83 megahertz.13. The ferromagnetic microdisk of claim 1 wherein the unique magneticvortex resonance frequency is about 162 megahertz.
 14. The ferromagneticmicrodisk of claim 1 wherein the unique magnetic vortex resonancefrequency is about 272 megahertz.
 15. The ferromagnetic microdisk ofclaim 1 wherein the molecular probe is attached to the surface of theferromagnetic microdisk.
 16. The ferromagnetic microdisk of claim 1wherein the molecular probe is selected from the group consisting ofDNA, RNA, antibody, protein, antibody fragments, antigens, epitopes,lectins, proteins, polypeptides, receptor proteins, ligands, hormones,vitamins, metabolites, substrates, inhibitors, cofactors,pharmaceuticals, aptamers, cytokines and neurotransmitters.
 17. Theferromagnetic microdisk of claim 1 wherein the molecular probe isselected from the group consisting of a small molecule, biomolecule, ornanomaterial.
 18. The ferromagnetic microdisk of claim 1 wherein themolecular probe is functional to bind to one or more bioanalytes ofinterest.
 19. The ferromagnetic microdisk of claim 18 wherein thebioanlytes of interest is selected from the group consisting of aminoacids, peptides, polypeptides, proteins, glycoproteins, lipoproteins,nucleosides, nucleotides, oligonucleotides, nucleic acids, sugars,carbohydrates, oligosaccharides, polysaccharides, fatty acids, lipid,hormones, metabolites, cytokines, chemokines, receptors,neurotransmitters, antigens, allergens, antibody, substrates,metabolites, cofactors, inhibitors, drugs, pharmaceuticals, nutrients,prions, toxins, poisons, explosives, pesticides, chemical warfareagents, biohazardous agents, radioisotopes, vitamins, heterocyclicaromatic compounds, carcinogens, mutagens, narcotics, amphetamines,barbiturates, hallucinogens, waste products and contaminants.
 20. Theferromagnetic microdisk of claim 1, comprising only one type ofmolecular probe attached to the ferromagnetic microdisk, the only onetype of molecular probe being specific to one particular bioanalyte. 21.The ferromagnetic microdisk of claim 1, comprising a library ofmolecular probes attached to the ferromagnetic microdisk, the library ofmolecular probes being specific to a myriad of bioanalytes.
 22. Theferromagnetic microdisk of claim 1, wherein the ferromagnetic microdiskis bound to a solid or a semi solid substrate.
 23. A kit comprising oneor more of the ferromagnetic microdisks of claim
 1. 24. A methodcomprising: attaching one or more bioanalytes to a read line; contactingone or more of the ferromagnetic microdisks of claim 1 with the one ormore bioanalytes; conjugating at least a portion of the one or more ofthe ferromagnetic microdisks to the one or more bioanalytes; detectingpresence, quantity or location of the one or more bioanalytes bydetecting the unique magnetic vortex resonance frequencies of theconjugated portion of the one or more of the ferromagnetic microdisks.